Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

Regeneron has evolved from a discovery-stage biotech into a diversified, cash-generative commercial leader built around its “Science to Medicine” model and proprietary antibody platforms. Revenue is generated through U.S. product sales, sizable collaboration profits (especially with Sanofi for Dupixent and Bayer for Eylea), and recurring ex-U.S. royalty/profit-share streams. As of Q1 2026, results reflect strong top-line momentum driven by Dupixent, Eylea/Eylea HD, and Libtayo, each addressing large markets with meaningful unmet need. Dupixent’s broad safety/efficacy record across multiple inflammatory indications reinforces category leadership; Eylea HD’s extended durability reduces treatment burden and is central to defending retina share; and Libtayo anchors oncology leadership in non-melanoma skin cancers. A critical economic catalyst arrives mid-2026 as Regeneron completes repayment of the Sanofi development balance, which should unlock materially higher collaboration profits and reshape EPS power into the end of the decade.